CTOR — CITIUS ONCOLOGY, INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2022-12-08.
Performance
Technicals
Others in Healthcare
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2025-09-19 | Holuka Eugene Myron Director | Grant or award | 300.0K | 0.00 | 0 |
| 2025-09-19 | Czuczman Myron Chief Medical Officer | Grant or award | 825.0K | 0.00 | 0 |
| 2025-09-19 | Dutia Suren G Director | Grant or award | 300.0K | 0.00 | 0 |
| 2025-09-19 | Webb Carol Director | Grant or award | 300.0K | 0.00 | 0 |
| 2025-09-19 | MCGRATH DENNIS M Director | Grant or award | 300.0K | 0.00 | 0 |
| 2025-09-19 | Smith Robert Joseph Director | Grant or award | 300.0K | 0.00 | 0 |
| 2025-09-19 | Bartushak Jaime Chief Financial Officer | Grant or award | 825.0K | 0.00 | 0 |
| 2025-09-19 | Mazur Leonard L Chief Executive Officer | Grant or award | 1.7M | 0.00 | 0 |
| 2025-09-19 | HOLUBIAK MYRON Z Secretary | Grant or award | 850.0K | 0.00 | 0 |
| 2025-09-19 | Mayersohn Joel David Director | Grant or award | 300.0K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | 5.7M | 9.2M |
| BANK OF AMERICA CORP /DE/ | 2.4M | 3.8M |
| VANGUARD CAPITAL MANAGEMENT LLC | 331.6K | 534.8K |
| GEODE CAPITAL MANAGEMENT, LLC | 164.1K | 264.7K |
| VANGUARD FIDUCIARY TRUST CO | 75.6K | 121.9K |
| IFP Advisors, Inc | 66.6K | 107.4K |
| BlackRock, Inc. | 29.4K | 47.5K |
| NORTHERN TRUST CORP | 28.4K | 45.7K |
| STATE STREET CORP | 26.6K | 42.9K |
| UBS Group AG | 22.8K | 36.8K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 3 | 2026-08-14 | 2026-08-10 | on EDGAR ↗ |
| 424B3 | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 8-K | 2026-08-12 | 2026-08-07 | on EDGAR ↗ |
| 424B3 | 2026-08-05 | — | on EDGAR ↗ |
| 8-K | 2026-08-05 | 2026-08-05 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Citius Oncology, Inc. (CTOR) filed form 8-K · 2026-08-14 · SEC EDGAR
- Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update · 2026-08-14
- CITIUS ONCOLOGY, INC. (CTOR) filed form 3 · 2026-08-14 · SEC EDGAR
- CITIUS ONCOLOGY, INC. (CTOR) filed form 424B3 · 2026-08-14 · SEC EDGAR
- CITIUS ONCOLOGY, INC. (CTOR) filed form 10-Q · 2026-08-14 · SEC EDGAR
- CITIUS ONCOLOGY, INC. (CTOR) filed form 8-K · 2026-08-14 · SEC EDGAR
Ask the AI about CTOR
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →